IVA Inventiva SA

Inventiva receives FDA Breakthrough Therapy designation for lead drug candidate lanifibranor in NASH

Inventiva receives FDA Breakthrough Therapy designation for lead drug candidate lanifibranor in NASH
EN
12/10/2020

Underlying

IVAInventiva SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Inventiva SA

 PRESS RELEASE
Free
IVA INVENTIVA SA

Inventiva to Host Analyst and Investor Event on October 8, 2025

Inventiva to Host Analyst and Investor Event on October 8, 2025 Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in the second half of 2026Three renowned international experts and a patient representative will highlight key trends shaping the MASH treatment landscape Daix (France), New York City (New York, United States), September 24, 2025 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of ...

September 24, 2025 1 EN
 PRESS RELEASE
Free
IVA INVENTIVA SA

Inventiva organise un événement analystes et investisseurs le 8 octobr...

Inventiva organise un événement analystes et investisseurs le 8 octobre 2025 Le programme inclura une mise à jour sur son médicament candidat, lanifibranor, en amont des résultats principaux de l’étude de Phase 3 NATiV3 attendus au second semestre 2026Trois experts internationaux de renom et un représentant des patients mettront en lumière les principales les évolutions qui définissent le paysage thérapeutique de la MASH Daix (France), New York City (New York, Etats-Unis), le 24 septembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharm...

September 24, 2025 1 EN
Jacob Mekhael ... (+2)
  • Jacob Mekhael
  • Mathijs Geerts Danau
UCB UCB S.A.
ZLDPF Zealand Pharma ... ... (+10)

Life Sciences Conference 25 Sep 2025

KBC Securities will host its annual life sciences conference on 25 September in Brussels. The event will include 14 exciting companies, both public and private, from the BeNeLux ecosystem and beyond. In this conference note, we provide an overview of the attending companies, as well as an outlook on KBC Securities' life sciences broader coverage.

UCB UCB S.A.
ZLDPF ZEALAND PHARMA A/S
IVA INVENTIVA SA
AUTL AUTOLUS THERAPEUTICS ADS
SEQUA SEQUANA MEDICAL
HYL HYLORIS PHARMACEUTICALS
PHVS PHARVARIS NV
MAAT MAAT PHARMA SA
ONWD ONWARD MEDICAL NV
MDXH MDXHEALTH
09/24/25 September 24, 2025 1 EN
 PRESS RELEASE
Free
IVA INVENTIVA SA

Inventiva to Participate in Upcoming September Investor Conferences

Inventiva to Participate in Upcoming September Investor Conferences Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in the following upcoming investor events:  H.C. Wainwright 27th Annual Global Investment ConferenceDate: Tuesday, September 9, 2025Time of the fi...

September 4, 2025 1 EN
 PRESS RELEASE
Free
IVA INVENTIVA SA

Inventiva annonce sa participation à plusieurs conférences investisseu...

Inventiva annonce sa participation à plusieurs conférences investisseurs en septembre Daix (France), New York City (New York, Etats-Unis), le 4 septembre 2025 – (Euronext Paris et Nasdaq : ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que son équipe de direction participera aux conférences investisseurs suivantes :H.C. Wainwright 27th Annual Global Investment Conference Date : Mardi 9 septembre 2025Heur...

September 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch